Business
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ANN ARBOR, Mich., May 18, 2026--ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update.
About this update from Endra Life Sciences Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/eafff37f1abf1fb3de81845fb91cc19c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zkI_KZuobfnI.lpDJD8jpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/eafff37f1abf1fb3de81845fb91cc19c","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hr9lDU_OfNW_316tlOvabQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/eafff37f1abf1fb3de81845fb91cc19c","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9I8YhyCo7AxWsN8wikjfJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/eafff37f1abf1fb3de81845fb91cc19c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"ANN ARBOR, Mich., May 18, 2026--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update.","length":354,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initiated Evaluation of Strategic Alternatives","length":46,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value.","length":166,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ENDRA will continue to execute on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.","length":159,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":325,"olType":false}]},{"val":[{"type":"text","content":"Demonstrated Strong Clinical Progress with TAEUS® Liver","length":55,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"On May 14, 2026, the Company announced multi-site clinical...